Disclosed is a use of ulipristal, or any metabolite thereof, in the manufacture of a medicament for the treatment of pain/bleeding/anaemia associated with dislocation of the endometrium, wherein the ulipristal is formulated for administration at a daily dosage at a therapeutically effective amount of 5 to 12 mg.